Clinical Data From Infinity Pharmaceuticals, Inc.'s Hsp90 Chaperone Inhibitor Program to be Presented During American Society of Clinical Oncology Meeting
CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting clinical data on its novel Hsp90 chaperone inhibitor, IPI-504, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Fla. from May 29 through June 2, 2009.